Dianthus Therapeutics, Inc. /DE/ (DNTH) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $6.39M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $7.47M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $6.39M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $6.39M |
| Deferred revenue · latest quarter (USD) | $7.47M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $1.52M + $5.94M ≈ $7.47M |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 41.25M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 6.39M USD | Accounts Payable, Current |
| Total deferred revenue | 7.47M USD | Deferred Revenue, Current · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | 1.52M USD | Deferred Revenue, Current |
| Deferred revenue due after one year | 5.94M USD | Deferred Revenue, Noncurrent · Deferred Revenue, Current |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | 0.00 USD | Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $1.29M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.39M | $7.47M | (m) | (m) | $41.25M | (m) | $1.52M | $5.94M | (m) | $0.00 |
| 2026-03-31 | (m) | $5.27M | $7.81M | (m) | (m) | $45.57M | (m) | $1.49M | $6.32M | (m) | $0.00 |
| 2025-12-31 | (m) | $9.72M | $6.96M | (m) | (m) | $37.52M | (m) | $1.19M | $5.77M | (m) | $0.00 |
| 2025-09-30 | (m) | $6.71M | $7.02M | (m) | (m) | $30.99M | (m) | $954.00K | $6.07M | (m) | $0.00 |
| 2025-06-30 | (m) | $5.40M | $2.26M | (m) | (m) | $23.00M | (m) | $479.00K | $1.78M | (m) | $0.00 |
| 2025-03-31 | (m) | $8.27M | $2.33M | (m) | (m) | $19.97M | (m) | $479.00K | $1.85M | (m) | $0.00 |
| 2024-12-31 | (m) | $4.58M | $2.39M | (m) | (m) | $21.53M | (m) | $479.00K | $1.91M | (m) | $0.00 |
| 2024-09-30 | (m) | $7.57M | $740.00K | (m) | (m) | $16.35M | (m) | $100.00K | $640.00K | (m) | $0.00 |
| 2024-06-30 | (m) | $3.69M | $782.00K | (m) | (m) | $10.74M | (m) | $100.00K | $682.00K | (m) | $0.00 |
| 2024-03-31 | (m) | $2.61M | $819.00K | (m) | (m) | $9.78M | (m) | $100.00K | $719.00K | (m) | $0.00 |
| 2023-12-31 | (m) | $2.61M | $836.00K | (m) | (m) | $10.54M | (m) | $100.00K | $736.00K | (m) | $0.00 |
| 2023-09-30 | (m) | $1.37M | $845.00K | (m) | (m) | $14.08M | (m) | $100.00K | $745.00K | (m) | $0.00 |
| 2023-06-30 | (m) | $813.00K | (m) | (m) | (m) | $4.03M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $1.08M | (m) | (m) | (m) | $5.98M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $2.45M | (m) | (m) | (m) | $40.69M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $2.58M | (m) | (m) | (m) | $40.10M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $2.05M | (m) | (m) | (m) | $39.44M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $4.44M | (m) | (m) | (m) | $43.20M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.04M | (m) | (m) | (m) | $17.26M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $1.89M | (m) | (m) | (m) | $16.55M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $2.93M | (m) | (m) | (m) | $17.49M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $2.11M | (m) | (m) | (m) | $15.56M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.76M | (m) | (m) | (m) | $17.71M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $2.39M | (m) | (m) | (m) | $16.07M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $2.65M | (m) | (m) | (m) | $16.81M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $3.95M | (m) | (m) | (m) | $19.04M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.81M | (m) | (m) | (m) | $20.32M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $2.04M | (m) | (m) | (m) | $15.70M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.35M | (m) | (m) | (m) | $15.88M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.01M | (m) | (m) | (m) | $13.69M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $3.49M | (m) | (m) | (m) | $11.66M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $4.90M | (m) | (m) | (m) | $13.01M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $1.50M | (m) | (m) | (m) | $8.40M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $167.00K | (m) | (m) | (m) | $4.14M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |